Digital Sponsored Webinar wrap-up: How pharma can leverage AI-driven synthetic... Synthetic personas turn static, traditional personas into interactive, evidence-backed simulations.
Digital Cracking the code: Unlocking key opinion leaders in the digi... With new guidance, treatment pathways, and medical advances emerging on a regular basis, the pursuit of knowledge and innovation is a never-ending process for healthcare providers.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.